Subscribe to our newsletter to receive the latest product updates and special offers

Order by Signal Tickers
Filters
Overview Valuation Financial Ownership Performance Technical ETF ETF Perf Custom Charts Tickers Basic TA News Snapshot Maps Stats
#191 / 200 Total
GROV - Grove Collaborative Holdings Inc. - Stock Price Chart
TickerGROV [NYSE]
CompanyGrove Collaborative Holdings Inc.
CountryUSA
IndustryHousehold & Personal Products
Market Cap61.47MEPS (ttm)-0.99
P/E-EPS this Y57.03%
Forward P/E-EPS next Y87.27%
PEG-EPS past 5Y-
P/S0.25EPS next 5Y-
P/B8.18EPS Q/Q-26.10%
Dividend-Sales Q/Q-25.18%
Insider Own56.70%Inst Own15.31%
Insider Trans0.13%Inst Trans76.97%
Short Float6.83%EarningsMay 14/a
Analyst Recom1.00Target Price3.00
Avg Volume75.71K52W Range1.37 - 3.81
Grove Collaborative Holdings, Inc. engages in the business of innovating sustainability-oriented consumer products. The firm is also involved in transforming consumer products into a positive force for human and environmental good. The company was founded by Stuart Landesberg and Christopher Clark in 2012 and is headquartered in San Francisco, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Clark ChristopherChief Technology OfficerJun 03 '24Sale1.596,48510,337118,829Jun 04 01:13 PM
Yurcisin Jeffrey MichaelPresident & CEOMay 31 '24Buy1.669,00014,94052,923May 31 07:12 PM
Yurcisin Jeffrey MichaelPresident & CEOMay 30 '24Buy1.617,50012,07543,923May 31 07:12 PM
Yurcisin Jeffrey MichaelPresident & CEOMay 29 '24Buy1.5660093636,423May 31 07:12 PM
Clark ChristopherChief Technology OfficerMay 01 '24Sale1.506,4859,72888,471May 02 03:52 PM
CADL - Candel Therapeutics Inc - Stock Price Chart
TickerCADL [NASD]
CompanyCandel Therapeutics Inc
CountryUSA
IndustryBiotechnology
Market Cap199.99MEPS (ttm)-1.29
P/E-EPS this Y-
Forward P/E-EPS next Y-
PEG-EPS past 5Y-46.75%
P/S-EPS next 5Y-
P/B32.98EPS Q/Q7.40%
Dividend-Sales Q/Q-
Insider Own36.47%Inst Own5.11%
Insider Trans0.00%Inst Trans-0.70%
Short Float8.20%EarningsMay 14/b
Analyst Recom1.00Target Price11.00
Avg Volume5.67M52W Range0.66 - 14.30
Candel Therapeutics, Inc. is a late clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.
BMTX - BM Technologies Inc - Stock Price Chart
TickerBMTX [AMEX]
CompanyBM Technologies Inc
CountryUSA
IndustrySoftware - Application
Market Cap30.97MEPS (ttm)-1.01
P/E-EPS this Y92.67%
Forward P/E8.86EPS next Y363.64%
PEG-EPS past 5Y-
P/S0.53EPS next 5Y-
P/B1.00EPS Q/Q114.90%
Dividend-Sales Q/Q20.00%
Insider Own28.95%Inst Own27.99%
Insider Trans0.00%Inst Trans-11.27%
Short Float2.83%EarningsMay 16/b
Analyst Recom1.67Target Price5.42
Avg Volume247.91K52W Range1.41 - 3.91
BM Technologies, Inc. is a technology company that provides banking services through its partner banks. It offers a mobile banking platform in the U.S. that provides access to checking and savings accounts, personal loans and credit cards. The company's operating model enables partner banks to provide banking services to low and middle-income Americans who have been left behind by the fee model of traditional banks. The company was founded by Luvleen Sidhu in 2016 and is headquartered in Wayne, PA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Donahue James M.President & CTOApr 30 '24Option Exercise0.00760077,132May 14 04:01 PM
Sidhu LuvleenChief Executive OfficerApr 30 '24Option Exercise0.008800701,201May 14 04:01 PM
Taylor WarrenExecutive Vice PresidentApr 30 '24Option Exercise0.00670039,142May 14 04:01 PM
Donahue James M.President & CTOMar 31 '24Option Exercise0.0018,750083,542Apr 02 04:56 PM
Sidhu LuvleenChief Executive OfficerMar 31 '24Option Exercise0.0025,0000711,441Apr 02 04:58 PM
IINN - Inspira Technologies Oxy B.H.N. Ltd - Stock Price Chart
TickerIINN [NASD]
CompanyInspira Technologies Oxy B.H.N. Ltd
CountryIsrael
IndustryMedical Devices
Market Cap28.18MEPS (ttm)-0.72
P/E-EPS this Y-
Forward P/E-EPS next Y-
PEG-EPS past 5Y-28.83%
P/S-EPS next 5Y-
P/B4.45EPS Q/Q95.19%
Dividend-Sales Q/Q-
Insider Own9.47%Inst Own0.54%
Insider Trans0.00%Inst Trans47.75%
Short Float1.28%Earnings-
Analyst Recom1.00Target Price13.00
Avg Volume201.08K52W Range0.76 - 2.49
Inspira Technologies Oxy B.H.N. Ltd. is a specialty medical device company, which engages in research, development, manufacturing, and marketing of proprietary life support technology with a vision to supersede traditional mechanical ventilators, or Mechanical Ventilation, which is the standard of care today for the treatment of acute respiratory failure. The company was founded by Dagi Shahar Ben Noon, Joe Hayon, and Udi Nussinovitch in July 2017 and is headquartered in Raanana, Israel.
EWTX - Edgewise Therapeutics Inc - Stock Price Chart
TickerEWTX [NASD, RUT]
CompanyEdgewise Therapeutics Inc
CountryUSA
IndustryBiotechnology
Market Cap1.51BEPS (ttm)-1.53
P/E-EPS this Y0.18%
Forward P/E-EPS next Y-25.72%
PEG-EPS past 5Y-68.02%
P/S-EPS next 5Y-
P/B2.82EPS Q/Q9.75%
Dividend-Sales Q/Q-
Insider Own29.73%Inst Own69.14%
Insider Trans2.19%Inst Trans15.17%
Short Float9.91%EarningsMay 09/b
Analyst Recom1.00Target Price32.50
Avg Volume598.36K52W Range5.12 - 21.60
Edgewise Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It focuses on the discovery, development and commercialization of innovative treatments for severe, rare muscle disorders for which there is significant unmet medical need. Its platform utilizes custom-built throughput and translatable systems that measure integrated muscle function in whole organ extracts to identify small molecule precision medicines regulating key proteins in muscle tissue, initially focused on addressing rare neuromuscular and cardiac diseases. The company was founded by Badreddin Edris, Alan Russel and Peter A. Thompson in 2017 and is headquartered in Boulder, CO.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Donovan Joanne M.CMOMay 02 '24Sale18.913,68269,62719,897May 03 06:27 PM
KOCH KEVINPresident and CEOMay 02 '24Sale18.913,15259,60414,478May 03 06:26 PM
Carruthers R MichaelChief Financial OfficerMay 02 '24Sale18.912,15740,78935,230May 03 06:30 PM
MOORE JOHN RGeneral CounselMay 02 '24Sale18.911,95636,9883,252May 03 06:31 PM
Derakhshan BehradChief Business OfficerMay 02 '24Sale18.911,71832,48713,422May 03 06:29 PM
APLT - Applied Therapeutics Inc - Stock Price Chart
TickerAPLT [NASD]
CompanyApplied Therapeutics Inc
CountryUSA
IndustryBiotechnology
Market Cap514.22MEPS (ttm)-1.32
P/E-EPS this Y12.40%
Forward P/E-EPS next Y62.95%
PEG-EPS past 5Y-8.72%
P/S48.24EPS next 5Y-
P/B7.64EPS Q/Q-123.12%
Dividend-Sales Q/Q-
Insider Own22.81%Inst Own72.60%
Insider Trans-3.37%Inst Trans-5.86%
Short Float4.85%EarningsMay 09/b
Analyst Recom1.20Target Price11.40
Avg Volume805.92K52W Range1.18 - 9.39
Applied Therapeutics, Inc. is a clinical-stage biopharmaceutical company which engages in the development of a pipeline of novel products. It is targeting treatments for central nervous system rare diseases and diabetic complications. The company was founded by Shoshana Shendelman on January 20, 2016 and is headquartered in New York, NY.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Shendelman ShoshanaPresident and CEOJun 06 '24Sale4.3261,795266,9543,756,019Jun 10 04:29 PM
Perfetti RiccardoChief Medical OfficerJun 06 '24Sale4.3222,00395,0531,009,534Jun 10 04:28 PM
Funtleyder Leslie D.Chief Financial OfficerJun 06 '24Sale4.3216,98073,354291,441Jun 10 04:25 PM
ALEXANDRIA REAL ESTATE EQUITIE10% OwnerJun 05 '24Sale4.24150,000636,0005,855,077Jun 06 06:45 PM
ALEXANDRIA REAL ESTATE EQUITIE10% OwnerJun 04 '24Sale4.21150,000631,5006,005,077Jun 06 06:45 PM
ABOS - Acumen Pharmaceuticals Inc - Stock Price Chart
TickerABOS [NASD]
CompanyAcumen Pharmaceuticals Inc
CountryUSA
IndustryBiotechnology
Market Cap139.99MEPS (ttm)-1.06
P/E-EPS this Y-7.39%
Forward P/E-EPS next Y-22.04%
PEG-EPS past 5Y-54.03%
P/S-EPS next 5Y-0.20%
P/B0.53EPS Q/Q9.76%
Dividend-Sales Q/Q-
Insider Own26.14%Inst Own63.81%
Insider Trans-0.22%Inst Trans4.20%
Short Float1.60%EarningsMay 14/b
Analyst Recom1.00Target Price12.80
Avg Volume278.46K52W Range1.81 - 11.31
Acumen Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which discovers and develops medicines and diagnostics for Alzheimer's disease. The company was founded by William L. Klein, Grant A. Krafft, and Caleb Finch in 1996 and is headquartered in Charlottesville, VA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
OConnell Daniel JosephPresident and CEOJan 19 '24Sale3.4715,20052,753502,485Jan 19 07:07 PM
Meisner Derek MChief Legal Officer & Corp SecJan 19 '24Sale3.488,93331,048108,867Jan 19 07:06 PM
Zuga MattCFO & Chief Business OfficerJan 18 '24Sale3.714,24215,717211,445Jan 19 07:05 PM
Siemers EricChief Medical OfficerJan 18 '24Sale3.713,12411,604117,576Jan 19 07:05 PM
Barton RussellChief Operating OfficerJan 18 '24Sale3.732,83310,55596,867Jan 19 07:04 PM
GALT - Galectin Therapeutics Inc - Stock Price Chart
TickerGALT [NASD]
CompanyGalectin Therapeutics Inc
CountryUSA
IndustryBiotechnology
Market Cap144.81MEPS (ttm)-0.74
P/E-EPS this Y10.81%
Forward P/E-EPS next Y-140.91%
PEG-EPS past 5Y-14.30%
P/S-EPS next 5Y-
P/B-EPS Q/Q4.28%
Dividend-Sales Q/Q-
Insider Own31.27%Inst Own12.26%
Insider Trans-0.10%Inst Trans-1.45%
Short Float8.94%EarningsMay 15/b
Analyst Recom1.00Target Price11.00
Avg Volume193.11K52W Range1.28 - 4.27
Galectin Therapeutics, Inc. is a biotechnology company, which engages in drug research and development to create new therapies for fibrotic disease, severe skin disease, and cancer. Its programs target the development of carbohydrate molecules which offers alternative options to larger market segments. The company was founded by James C. Czirr and Anatole A. Klyosov on July 10, 2000 and is headquartered in Norcross, GA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Zordani Richard A. Jr.DirectorApr 30 '24Buy3.521,0003,5201,000Apr 30 02:14 PM
LEWIS JOELPresident and CEOApr 24 '24Buy3.391,0003,3902,000Apr 25 01:27 PM
CZIRR JAMES C10% OwnerApr 23 '24Sale3.063,67711,2525,922,207Apr 25 11:36 AM
FREEMAN KEVIN DDirectorApr 22 '24Buy2.982,5007,45025,969Apr 22 04:04 PM
CZIRR JAMES C10% OwnerApr 22 '24Sale3.0621,32365,2485,925,884Apr 25 11:36 AM
ALEC - Alector Inc - Stock Price Chart
TickerALEC [NASD, RUT]
CompanyAlector Inc
CountryUSA
IndustryBiotechnology
Market Cap410.58MEPS (ttm)-1.39
P/E-EPS this Y-26.41%
Forward P/E-EPS next Y15.72%
PEG-EPS past 5Y-15.76%
P/S4.26EPS next 5Y-10.70%
P/B2.30EPS Q/Q30.30%
Dividend-Sales Q/Q-3.96%
Insider Own21.98%Inst Own75.51%
Insider Trans-0.44%Inst Trans0.70%
Short Float11.40%EarningsMay 08/a
Analyst Recom1.90Target Price13.75
Avg Volume589.08K52W Range3.66 - 9.06
Alector, Inc. operates as a clinical-stage biopharmaceutical company, which engages in pioneering of immuno-neurology. It develops portfolio of innate immune system programs, designed to functionally repair genetic mutations and enable the rejuvenated immune cells to counteract emerging brain pathologies. Its treatment targets immune dysfunction as a root cause of multiple pathologies that are drivers of degenerative brain disorders. The company was founded by Asa Abeliovich, Errik B. Anderson, Tillman U. Gerngross, and Arnon Rosenthal in May 2013 and is headquartered in South San Francisco, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Rosenthal ArnonChief Executive OfficerJun 03 '24Sale4.8025,135120,6181,975,245Jun 04 06:05 PM
Kenkare-Mitra SaraPresident and Head of R&DJun 03 '24Sale4.8013,20663,373305,641Jun 04 06:05 PM
Romano GaryChief Medical OfficerJun 03 '24Sale4.808,04038,582188,273Jun 04 06:05 PM
GRASSO MARCChief Financial OfficerJun 03 '24Sale4.806,92033,208138,037Jun 04 06:05 PM
Rosenthal ArnonChief Executive OfficerMar 04 '24Sale6.9218,837130,3862,000,380Mar 05 06:00 PM
ATYR - Atyr Pharma Inc - Stock Price Chart
TickerATYR [NASD]
CompanyAtyr Pharma Inc
CountryUSA
IndustryBiotechnology
Market Cap113.87MEPS (ttm)-0.90
P/E-EPS this Y0.85%
Forward P/E-EPS next Y19.74%
PEG-EPS past 5Y43.36%
P/S192.99EPS next 5Y13.00%
P/B1.34EPS Q/Q17.81%
Dividend-Sales Q/Q-
Insider Own2.86%Inst Own60.52%
Insider Trans4.14%Inst Trans0.60%
Short Float0.52%EarningsMay 02/a
Analyst Recom1.00Target Price24.60
Avg Volume478.72K52W Range1.08 - 2.44
aTyr Pharma, Inc. engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
DENYES NANCYGeneral CounselJun 05 '24Buy1.865,0009,27622,267Jun 06 08:26 AM
Shukla SanjayPresident and CEOMay 31 '24Buy1.8120,00036,140136,548Jun 03 08:34 AM
Broadfoot Jill MarieChief Financial OfficerMay 31 '24Buy1.795,0008,95027,960Jun 03 08:38 AM
COUGHLIN TIMOTHYDirectorMay 30 '24Buy1.7550,00087,50056,000Jun 03 04:21 PM
Broadfoot Jill MarieChief Financial OfficerFeb 06 '24Sale1.691,5902,68720,821Feb 06 08:18 PM
110151617181920